Table 2.
Formulation | Size, nm | r1, s −1 mM −1 | r2, s −1 mM −1 | Blood half-life apoE−/−, h | Blood half-life WT, h | %ID in liver (24 hrs p.i) |
---|---|---|---|---|---|---|
Untargeted LUSPIO | 10 ± 3 | 14 ± 1 | 35 ± 2 | 1.52 | 1.41 | 25 |
Untargeted LSPIO | 35 ± 5 | 12 ± 1 | 103 ± 4 | 1.02 | 1.01 | 35 |
MDA2 LUSPIO | 14 ± 3 | 13 ± 1 | 37 ± 2 | 9.01 | 1.55 | 31 |
MDA2 LSPIO | 38 ± 4 | 11 ± 1 | 117 ± 5 | 7.28 | 1.12 | 37 |
IK17 LUSPIO | 12 ± 2 | 14 ± 1 | 35 ± 2 | 9.12 | 31 | |
IK17 LSPIO | 36 ± 4 | 10 ± 1 | 106 ± 5 | 7.30 | 34 | |
E06 LUSPIO | 16 ± 4 | 12 ± 1 | 38 ± 2 | 9.32 | 30 | |
E06 LSPIO | 39 ± 5 | 11 ± 1 | 119 ± 6 | 7.42 | 35 |
All sizes are based upon the weighted number averages. The relaxivities shown were obtained in buffer at 60 MHz and 40°C. All blood half-lives and percent injected dose (%ID) in the liver were obtained in apoE−/− or wild-type (WT) mice after injection of a 3.9-mg Fe/Kg dose